Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Bronchodilator

Therapeutic area intelligence for Bronchodilator with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Companies
1

Companies

Lupin →

Assets

Cipla →
FDA →
Nephron →
Revefenacin →

Recent signals(6)

RegulatoryJuly 28, 2026

Cipla's Albuterol Sulfate ANDA219409 Receives FDA Approval Status

Cipla's application for Albuterol Sulfate (ANDA219409) has received an approval status of AP from the FDA.

RegulatoryJuly 20, 2026

Nephron's Levalbuterol Hydrochloride ANDA215217 Receives Approval Status

Nephron's ANDA for Levalbuterol Hydrochloride has received an approval status (AP) from the FDA.

RegulatoryJuly 18, 2026

Lupin Inc. Submits ANDA for Revefenacin to FDA

Lupin Inc. has submitted an Abbreviated New Drug Application (ANDA) for Revefenacin, currently under standard review.

StrategyJuly 15, 2026

FDA Grants Approval for Ephedrine Sulfate ANDA216740 by Baxter Healthcare

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) for Ephedrine Sulfate submitted by Baxter Healthcare.

RegulatoryJuly 5, 2026

Cipla's Albuterol Sulfate ANDA219409 Receives AP Status from FDA

Cipla's application for Albuterol Sulfate has received an Abbreviated Approval (AP) status from the FDA.

StrategyJune 20, 2026

FDA Approves Albuterol Sulfate ANDA219409 from Cipla

The FDA has approved ANDA219409 for Albuterol Sulfate submitted by Cipla.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.